医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
3期
90-91
,共2页
抗高血压药%缬沙坦%血压监测仪%左室肥厚
抗高血壓藥%纈沙坦%血壓鑑測儀%左室肥厚
항고혈압약%힐사탄%혈압감측의%좌실비후
antihypertensive drugs%indapamide blood pressure%left ventricular hypertrophy
目的评价缬沙坦的长效降压效果及安全性.方法2010年7月至2012年6月我科及住院收治的216例轻,中度高血压病患者[男性118例,女性98例,平均年龄(51±11)岁]服用安慰剂2周后及服用缬沙坦胶囊80mg8周,分别于早晨8:00来医院佩带24h动态血压监测仪,进行连续30h动态血压测定,计算谷/峰比值(T/P)及每小时平均血压,同时在服缬沙坦80mg的第2.4.8周诊所测坐位血压.药物安全性主要观察血钾及血尿酸.结果216例轻.中度高血压患者服药后通过诊所测坐位血压评价,降压总有效率为67.7﹪;24h动态血压监测结果按全部患者计算或有效病例计算,T/P比值结果相近.全组计算收缩压(SBP)与舒张压(DBP)的T/P比值分别为0.81和0.80.服缬沙坦胶囊与服安慰剂后第25-30h动态血压监测发现,血压分别为(134.2±12.1)/(89.2±9.1) mmHg(1mmHg=0.133kpa)及(142.2±12.1)/(92.2±7.2)mmHg(P<0.01).对24h动态血压最大降压幅度≥20/10mmHg的66例有反应者,分析其最大降压时间,93﹪在8-19h.其中14-17h为最高峰.服药后血尿酸轻度升高者36例(16.7﹪).结论缬沙坦能够在24h很好的控制血压.若患者偶尔延后服药时间,它至少能在服药后的25-30h之间稳定降压.达峰时间延迟到14-17h,可能与其降低左室肥厚有关.
目的評價纈沙坦的長效降壓效果及安全性.方法2010年7月至2012年6月我科及住院收治的216例輕,中度高血壓病患者[男性118例,女性98例,平均年齡(51±11)歲]服用安慰劑2週後及服用纈沙坦膠囊80mg8週,分彆于早晨8:00來醫院珮帶24h動態血壓鑑測儀,進行連續30h動態血壓測定,計算穀/峰比值(T/P)及每小時平均血壓,同時在服纈沙坦80mg的第2.4.8週診所測坐位血壓.藥物安全性主要觀察血鉀及血尿痠.結果216例輕.中度高血壓患者服藥後通過診所測坐位血壓評價,降壓總有效率為67.7﹪;24h動態血壓鑑測結果按全部患者計算或有效病例計算,T/P比值結果相近.全組計算收縮壓(SBP)與舒張壓(DBP)的T/P比值分彆為0.81和0.80.服纈沙坦膠囊與服安慰劑後第25-30h動態血壓鑑測髮現,血壓分彆為(134.2±12.1)/(89.2±9.1) mmHg(1mmHg=0.133kpa)及(142.2±12.1)/(92.2±7.2)mmHg(P<0.01).對24h動態血壓最大降壓幅度≥20/10mmHg的66例有反應者,分析其最大降壓時間,93﹪在8-19h.其中14-17h為最高峰.服藥後血尿痠輕度升高者36例(16.7﹪).結論纈沙坦能夠在24h很好的控製血壓.若患者偶爾延後服藥時間,它至少能在服藥後的25-30h之間穩定降壓.達峰時間延遲到14-17h,可能與其降低左室肥厚有關.
목적평개힐사탄적장효강압효과급안전성.방법2010년7월지2012년6월아과급주원수치적216례경,중도고혈압병환자[남성118례,녀성98례,평균년령(51±11)세]복용안위제2주후급복용힐사탄효낭80mg8주,분별우조신8:00래의원패대24h동태혈압감측의,진행련속30h동태혈압측정,계산곡/봉비치(T/P)급매소시평균혈압,동시재복힐사탄80mg적제2.4.8주진소측좌위혈압.약물안전성주요관찰혈갑급혈뇨산.결과216례경.중도고혈압환자복약후통과진소측좌위혈압평개,강압총유효솔위67.7﹪;24h동태혈압감측결과안전부환자계산혹유효병례계산,T/P비치결과상근.전조계산수축압(SBP)여서장압(DBP)적T/P비치분별위0.81화0.80.복힐사탄효낭여복안위제후제25-30h동태혈압감측발현,혈압분별위(134.2±12.1)/(89.2±9.1) mmHg(1mmHg=0.133kpa)급(142.2±12.1)/(92.2±7.2)mmHg(P<0.01).대24h동태혈압최대강압폭도≥20/10mmHg적66례유반응자,분석기최대강압시간,93﹪재8-19h.기중14-17h위최고봉.복약후혈뇨산경도승고자36례(16.7﹪).결론힐사탄능구재24h흔호적공제혈압.약환자우이연후복약시간,타지소능재복약후적25-30h지간은정강압.체봉시간연지도14-17h,가능여기강저좌실비후유관.
Objective To evaluate the effect of valsartan on the long-acting antihypertensive effect and safety. Methods from 2010 July to 2012 June in our department and hospital treated 216 cases of light. Moderate hypertension patients (118 males, 98 females, mean age (51±11) years old) with placebo after 2 weeks and administration of valsartan capsules 80mg8 weeks, respectively in the morning 8:00 dynamic blood pressure monitor with 24h hospital, were continuous 30h ambulatory blood pressure measurement, calculation of trough/ peak ratio (T/P) and hourly mean blood pressure, while in the service of valsartan 80mg week 2.4.8 clinic sitting blood pressure measurement. Drug safety on serum potassium and uric acid. Results 216 cases of mild moderate hypertension patients after taking the medicine. Through clinic sitting blood pressure measurement evaluation, total effective rate was 67.7﹪;24h ambulatory blood pressure monitoring in al patients results calculated or effective case calculation, the ratio of T/P results similar to. Al the calculations of systolic and diastolic blood pressure (SBP) (DBP) T/P ratio were 0.81 and 0.80. suit valsartan capsules and placebo after 25-30h ambulatory blood pressure monitoring, blood pressure were (134.2 ±12.1) /(89.2±9.1) mmHg (1mmHg=0.133kpa) and (142.2±12.1) / (92.2±7.2) mmHg (P<0.01). The 24h ambulatory blood pressure maximum pressure reduced≥ 20/10mmHg in 66 cases with reaction, analysis of its maximum decompression time, 93﹪ at 8 -19h. Where 14-17h is the highest peak. After taking blood uric acid increased slightly in 36 cases (16.7﹪). Conclusion valsartan can in 24h very good control of blood pressure. If the patient occasionaly delayed time of taking medicine, it can at least in after taking 25-30h between stable buck. Peak time delay to the 14-17h, may be associated with reduced left ventricular hypertrophy.
